1-6 of 6
Jessica Katz
Close
Sort by
Journal Articles

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Tracy T. Chow, Michael Amatangelo, Peilin Ma, Chad C. Bjorklund, Krista Wollerman, Tiziana Civardi, Phillip Koo, Yue Zhu, Paulo Maciag, Jessica Katz, Aparna Raval, Albert Oriol, Robert Z. Orlowski, Darrell White, Paul G. Richardson, Anita K. Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3318.
https://doi.org/10.1182/blood-2023-178881
Published: 2023
Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

Paul G. Richardson, Irwindeep Sandhu, Craig C. Hofmeister, Robert Z. Orlowski, Darrell White, Angelo Belotti, Charlotte Toftmann Hansen, Noopur S. Raje, Tracy T. Chow, Zehua Zhou, Tiziana Civardi, Phillip Koo, Yue Zhu, Jessica Katz, Albert Oriol
Journal: Blood
Blood (2023) 142 (Supplement 1): 1013.
https://doi.org/10.1182/blood-2023-174443
Published: 2023
Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 1366–1368.
https://doi.org/10.1182/blood-2022-157945
Published: 2022
Journal Articles

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Paul G. Richardson, Enrique Ocio, Noopur S. Raje, Tara Gregory, Darrell White, Albert Oriol, Irwindeep Sandhu, Marc-Steffen Raab, Richard LeBlanc, Cesar Rodriguez, Suzanne Trudel, Ralph Wäsch, Aurore Perrot, Nizar J. Bahlis, Zehua Zhou, Manisha Lamba, Michael Amatangelo, Tiziana Civardi, Jessica Katz, Paulo Maciag, Teresa Peluso, Meletios A. Dimopoulos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2731.
https://doi.org/10.1182/blood-2021-147812
Published: 2021
Journal Articles

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, Tiziana Civardi, Jessica Katz, Paulo Maciag, Patrick Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta
Journal: Blood
Blood (2021) 138 (Supplement 1): 1613.
https://doi.org/10.1182/blood-2021-153994
Published: 2021
Journal Articles

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

Meletios A. Dimopoulos, Sagar Lonial, MD, Darrell White, MD, Philippe Moreau, Antonio Palumbo, MD, Jesus San Miguel, MDPhD, Ofer Shpilberg, MD MPH, Kenneth C. Anderson, MD, Sebastian Grosicki, MD PhD, Ivan Spicka, MD PhD, Adam Walter-Croneck, Hila Magen-Nativ, Maria-Victoria Mateos, Andrew Belch, Donna Reece, Meral Beksac, MD, Eric Bleickhardt, Valerie Poulart, Jessica Katz, Anil K. Singhal, Paul G. Richardson
Journal: Blood
Blood (2015) 126 (23): 28.
https://doi.org/10.1182/blood.V126.23.28.28
Published: 2015